All In Biotech

Drug Trial Radar · NCT05529316

A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

A Multicohort, Open Label, Phase 2 Study of Botensilimab (AGEN1181) for Treatment of Advanced Melanoma Refractory to Prior Checkpoint Inhibitor Therapy

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

150

Actual

Start

Dec 12, 2022

Primary completion

Apr 27, 2026

Study completion Apr 27, 2026

Sponsor

Lead sponsor
Agenus Inc.Industry
Sponsor type
Industry
First posted
Sep 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open-label, 2-part, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab in participants with advanced cutaneous melanoma refractory to checkpoint inhibitor therapy.

Conditions

  • Advanced Melanoma

Interventions

  • BotensilimabDrug

    An anti-CTLA-4 monoclonal antibody

  • BalstilimabDrug

    An anti-PD-1 monoclonal antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response RateTime frame: Up to 40 months

Locations

51 sites in 10 countries. Site status is shown where the registry gives one.

  • Scottsdale Healthcare Hospitals DBA HonorHealth

    Scottsdale, Arizona

  • Virginia K. Crosson Cancer Center at St. Jude Medical Center

    Fullerton, California

  • Providence Saint John's Health Center

    Santa Monica, California

  • Yale University School of Medicine - Yale Cancer Center

    New Haven, Connecticut

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • John Theurer Cancer Center at Hackensack University Medical Center

    Hackensack, New Jersey

  • Universitair Ziekenhuis Brussel

    Jette, Belgium

  • Oncosite - Centro de Pesquisa Clinica Em Oncologia

    Ijuí, Brazil

  • Centro de Pesquisas Clinicas da Fundação Doutor Amaral Carvalho

    Jaú, Brazil

  • Centro Gaucho Integrado de Oncologia, Hematologia, Ensino e Pesquisa

    Porto Alegre, Brazil

  • INCA II - Instituto Nacional de Cancer Jose Alencar Gomes da Silva

    Rio de Janeiro, Brazil

  • Hospital Sirio Libanes

    São Paulo, Brazil

  • Real e Benemerita Associaçao Portuguesa de Beneficencia - A Beneficencia Portuguesa de Sao Paulo

    São Paulo, Brazil

  • Hospital A.C. Camargo Cancer Center

    São Paulo, Brazil

  • CHU Amiens Picardie - Hopital Sud

    Amiens, France

  • CHU Grenoble-Alpes - Hopital Michallon

    La Tronche, France

  • Centre Leon Berard

    Lyon, France

  • CHU de Nantes

    Nantes, France

  • AP-HP Hopital Saint-Louis

    Paris, France

  • Centre Eugene Marquis

    Rennes, France

  • Gustave Roussy

    Villejuif, France

  • Universitaetsklinikum Essen

    Essen, Germany

  • Universitaetsklinikum Hamburg-Eppendorf

    Hamburg, Germany

  • Universitaetsklinikum Heidelberg

    Heidelberg, Germany

  • University Hospital Schleswig-Holstein

    Kiel, Germany

  • Universitaetsmedizin der Johannes Gutenberg - Universitaet Mainz

    Mainz, Germany

  • Klinikum der Universitaet München

    München, Germany

  • Universitaetsklinikum Tuebingen

    Tübingen, Germany

  • Universitaetsklinikum Würzburg

    Würzburg, Germany

  • IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - IRST S.r.l.

    Meldola, Italy

  • Istituto Nazionale Tumori IRCCS Fondazione G. Pascale

    Naples, Italy

  • Azienda Ospedaliero Universitaria Senese

    Siena, Italy

  • Blokhin National Medical Research Oncology Centre

    Moscow, Russia

  • Branch Office of "Hadassah Medical Ltd"

    Moscow, Russia

  • Moscow City Oncology Hospital #62

    Moscow, Russia

  • LLC Medical Services

    Saint Petersburg, Russia

  • Clinical Hospital Russian Railways - Medicine

    Saint Petersburg, Russia

  • Petrov National Medical Research Center of Oncology

    Saint Petersburg, Russia

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.